NYSE: RVTYRevvity Inc Stock
$113.88-2.54 (-2.18%)
Updated Jan 10, 2025
RVTY Price
$113.88
Fair Value Price
N/A
Market Cap
$13.86B
52 Week Low
$97.32
52 Week High
$129.50
P/E
54.75x
P/B
1.75x
P/S
5.69x
PEG
0.47x
Dividend Yield
0.25%
Revenue
$2.72B
Earnings
$254.30M
Gross Margin
55.4%
Operating Margin
11.07%
Profit Margin
9.3%
Debt to Equity
0.61
Operating Cash Flow
$651M
Beta
0.86
Next Earnings
Jan 30, 2025
Ex-Dividend
Jan 17, 2025
Next Dividend
Feb 7, 2025
RVTY Overview
PerkinElmer, Inc. offers instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company serves laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer was founded in 1937 and is headquartered in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RVTY's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Value
B
Growth
C
Momentum
C
Sentiment
C
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RVTY news, forecast changes, insider trades & much more!
RVTY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RVTY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RVTY ($113.88) is trading above its intrinsic value of $90.52, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RVTY is poor value based on its earnings relative to its share price (54.75x), compared to the US market average (30.06x)
P/E vs Market Valuation
RVTY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more RVTY due diligence checks available for Premium users.
Valuation
RVTY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
54.75x
Industry
21.83x
Market
30.06x
RVTY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
RVTY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
RVTY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.75x
Industry
4.05x
RVTY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RVTY price to earnings growth (PEG)
For valuing profitable companies with growth potential
RVTY is good value based... subscribe to Premium to read more.
PEG Value Valuation
RVTY's financial health
Profit margin
Revenue
$684.0M
Net Income
$94.4M
Profit Margin
13.8%
RVTY's Earnings (EBIT) of $301.20M... subscribe to Premium to read more.
Interest Coverage Financials
RVTY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.8B
Liabilities
$4.8B
Debt to equity
0.61
RVTY's short-term assets ($2.45B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RVTY's long-term liabilities ($4.16B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RVTY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RVTY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$147.9M
Investing
$690.2M
Financing
-$873.7M
RVTY's operating cash flow ($650.68M)... subscribe to Premium to read more.
Debt Coverage Financials
RVTY vs Diagnostic & Research Stocks
Revvity Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.